(ROP) Roper Technologies - Ratings and Ratios
Software, Analytics, Payments, Metering, Sensors, Medical
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.94% |
| Yield on Cost 5y | 1.03% |
| Yield CAGR 5y | 10.03% |
| Payout Consistency | 94.6% |
| Payout Ratio | 17.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 17.7% |
| Value at Risk 5%th | 29.4% |
| Relative Tail Risk | 0.74% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.80 |
| Alpha | -25.00 |
| CAGR/Max DD | 0.05 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.386 |
| Beta | 0.588 |
| Beta Downside | 0.645 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.63% |
| Mean DD | 5.34% |
| Median DD | 3.61% |
Description: ROP Roper Technologies December 02, 2025
Roper Technologies (NASDAQ: ROP) operates as a diversified industrial conglomerate that designs and sells vertical-market software and technology-enabled products across North America, Europe, and Asia. Its portfolio is organized into three segments: (1) Application Software, delivering cloud-based solutions for K-12 education, transportation, insurance, and food-service; (2) Network Software, providing data-collaboration platforms, visual-effects tools, supply-chain and health-care software; and (3) Technology-Enabled Products, offering hardware such as ultrasound accessories, RFID readers, precision measurement systems, and medical devices. Distribution is a mix of direct sales offices, manufacturers’ representatives, and third-party resellers.
As of FY 2023, ROP reported revenue of roughly **$7.2 billion** and an operating margin of **≈15 %**, consistent with its historical 13-16 % range. The company has a **5-year dividend yield of ~0.6 %** and a **share-repurchase program** that has returned about **$1 billion** to shareholders since 2020. These figures suggest a cash-generative business, but the forward-looking earnings guidance remains uncertain due to the cyclical nature of its industrial customers.
Key economic drivers for ROP include: (i) **industrial automation spending**, which has a global CAGR of ~6 % and underpins demand for its precision-measurement and sensor products; (ii) **health-care reimbursement trends**, especially in the U.S., that affect adoption of its medical-device and software solutions; and (iii) **government and education budgets**, which influence the growth of its K-12 and public-sector software offerings. A slowdown in any of these macro-segments could materially impact segment revenue mix.
For a deeper, data-driven comparison of ROP’s valuation and risk profile, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (1.57b TTM) > 0 and > 6% of Revenue (6% = 463.3m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 0.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -17.12% (prev -25.05%; Δ 7.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 2.52b > Net Income 1.57b (YES >=105%, WARN >=100%) |
| Net Debt (9.13b) to EBITDA (3.38b) ratio: 2.70 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (108.3m) change vs 12m ago 0.19% (target <= -2.0% for YES) |
| Gross Margin 68.96% (prev 69.68%; Δ -0.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 23.35% (prev 21.47%; Δ 1.87pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.59 (EBITDA TTM 3.38b / Interest Expense TTM 302.5m) >= 6 (WARN >= 3) |
Altman Z'' 3.01
| (A) -0.04 = (Total Current Assets 1.80b - Total Current Liabilities 3.13b) / Total Assets 34.58b |
| (B) 0.49 = Retained Earnings (Balance) 16.88b / Total Assets 34.58b |
| (C) 0.07 = EBIT TTM 2.29b / Avg Total Assets 33.07b |
| (D) 1.15 = Book Value of Equity 16.77b / Total Liabilities 14.59b |
| Total Rating: 3.01 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.12
| 1. Piotroski 4.0pt |
| 2. FCF Yield 4.27% |
| 3. FCF Margin 31.86% |
| 4. Debt/Equity 0.47 |
| 5. Debt/Ebitda 2.70 |
| 6. ROIC - WACC (= -0.36)% |
| 7. RoE 8.08% |
| 8. Rev. Trend 99.77% |
| 9. EPS Trend -25.86% |
What is the price of ROP shares?
Over the past week, the price has changed by +0.16%, over one month by +1.47%, over three months by -10.01% and over the past year by -12.89%.
Is ROP a buy, sell or hold?
- Strong Buy: 10
- Buy: 2
- Hold: 6
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the ROP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 569.5 | 26.5% |
| Analysts Target Price | 569.5 | 26.5% |
| ValueRay Target Price | 419.4 | -6.8% |
ROP Fundamental Data Overview December 31, 2025
P/E Trailing = 31.0496
P/E Forward = 20.9644
P/S = 6.2851
P/B = 2.4272
P/EG = 1.9764
Beta = 0.938
Revenue TTM = 7.72b USD
EBIT TTM = 2.29b USD
EBITDA TTM = 3.38b USD
Long Term Debt = 9.15b USD (from longTermDebt, last quarter)
Short Term Debt = 300.0m USD (from shortTermDebt, last quarter)
Debt = 9.45b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.13b USD (from netDebt column, last quarter)
Enterprise Value = 57.66b USD (48.53b + Debt 9.45b - CCE 320.0m)
Interest Coverage Ratio = 7.59 (Ebit TTM 2.29b / Interest Expense TTM 302.5m)
FCF Yield = 4.27% (FCF TTM 2.46b / Enterprise Value 57.66b)
FCF Margin = 31.86% (FCF TTM 2.46b / Revenue TTM 7.72b)
Net Margin = 20.34% (Net Income TTM 1.57b / Revenue TTM 7.72b)
Gross Margin = 68.96% ((Revenue TTM 7.72b - Cost of Revenue TTM 2.40b) / Revenue TTM)
Gross Margin QoQ = 69.54% (prev 69.22%)
Tobins Q-Ratio = 1.67 (Enterprise Value 57.66b / Total Assets 34.58b)
Interest Expense / Debt = 0.95% (Interest Expense 89.7m / Debt 9.45b)
Taxrate = 20.01% (99.7m / 498.2m)
NOPAT = 1.84b (EBIT 2.29b * (1 - 20.01%))
Current Ratio = 0.58 (Total Current Assets 1.80b / Total Current Liabilities 3.13b)
Debt / Equity = 0.47 (Debt 9.45b / totalStockholderEquity, last quarter 19.99b)
Debt / EBITDA = 2.70 (Net Debt 9.13b / EBITDA 3.38b)
Debt / FCF = 3.71 (Net Debt 9.13b / FCF TTM 2.46b)
Total Stockholder Equity = 19.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.54% (Net Income 1.57b / Total Assets 34.58b)
RoE = 8.08% (Net Income TTM 1.57b / Total Stockholder Equity 19.43b)
RoCE = 8.03% (EBIT 2.29b / Capital Employed (Equity 19.43b + L.T.Debt 9.15b))
RoIC = 6.61% (NOPAT 1.84b / Invested Capital 27.78b)
WACC = 6.97% (E(48.53b)/V(57.98b) * Re(8.18%) + D(9.45b)/V(57.98b) * Rd(0.95%) * (1-Tc(0.20)))
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.28%
[DCF Debug] Terminal Value 79.71% ; FCFE base≈2.35b ; Y1≈2.69b ; Y5≈3.75b
Fair Price DCF = 587.3 (DCF Value 63.22b / Shares Outstanding 107.6m; 5y FCF grow 17.15% → 3.0% )
EPS Correlation: -25.86 | EPS CAGR: -45.41% | SUE: -4.0 | # QB: 0
Revenue Correlation: 99.77 | Revenue CAGR: 13.46% | SUE: -0.39 | # QB: 0
EPS next Quarter (2026-03-31): EPS=5.18 | Chg30d=+0.008 | Revisions Net=-4 | Analysts=13
EPS next Year (2026-12-31): EPS=21.62 | Chg30d=+0.000 | Revisions Net=-8 | Growth EPS=+8.5% | Growth Revenue=+8.8%
Additional Sources for ROP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle